中国医院用药评价与分析2025，Vol.25Issue(3)：358-361,367,5.DOI:10.14009/j.issn.1672-2124.2025.03.022
BRAvO评估表指导门诊儿科癫痫患者超说明书用药的风险获益管理研究
Risk and Benefit Management Study of BRAvO Assessment Scale in Guiding Off-Label Drug Use in Outpatient Pediatric Patients with Epilepsy
摘要
Abstract
OBJECTIVE:Using pediatric epilepsy as the research disease,to investigate the off-label drug use in outpatient pediatric patients in the hospital,and to establish a risk and benefit assessment system for off-label drug use in outpatient pediatrics.METHODS:The outpatient prescriptions of 1 400 patients diagnosed with epilepsy in the pediatrics of the hospital from 2021 to 2022 were analyzed,Logistic regression analysis was used to predict the independent factors affecting off-label drug use in pediatric epilepsy patients,the Benefit and Risk Assessment for Off-Label Use(BRAvO)assessment scale was used to analyze the off-label use of topiramate.RESULTS:Among 1 400 children with epilepsy in outpatient and emergency treatment,there were 112 cases of off-label drug use.Results of multivariate Logistic regression analysis showed that age and number of medication varieties were independent influencing factors on off-label drug use in children with epilepsy.The effectiveness of topiramate for children under 2 years was determined by using the BRAvO assessment scale,but the specific administration dosage was not determined.CONCLUSIONS:Off-label drug use remains a major problem for outpatient pediatric patients,the BRAvO assessment scale may provide decision-making for off-label drug use in outpatient pediatrics,standardize pediatric off-label drug use,and reduce the risk of off-label drug use.关键词
BRAvO评估表/门诊儿科患者/超说明书用药/风险获益评估Key words
BRAvO assessment scale/Outpatient pediatric patients/Off-label drug use/Risk and benefit assessment分类
医药卫生引用本文复制引用
李想,周静,陈刚,陈建坤,朱雯雯,袁玉丽..BRAvO评估表指导门诊儿科癫痫患者超说明书用药的风险获益管理研究[J].中国医院用药评价与分析,2025,25(3):358-361,367,5.基金项目
孝感市自然科学计划项目(No.XGKJ2020010021) （No.XGKJ2020010021）
